NCT02358395View on ClinicalTrials.gov

A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

November 30, 2017

Study Completion Date

November 30, 2017

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

BBI608

Administered continuously twice daily with doses separated by 9-15 hours.

DRUG

Sorafenib

Sorafenib 400 mg twice daily (800 mg total daily dose).

Trial Locations (1)

Unknown

4 Sites, Tokyo,etc

All Listed Sponsors
lead

Sumitomo Pharma Co., Ltd.

INDUSTRY

NCT02358395 - A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter